BCRX - BioCryst Pharmaceuticals, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 8.35 |
| Open | 8.30 |
| Bid | 8.33 x 1400 |
| Ask | 8.40 x 3000 |
| Day's Range | 8.24 - 8.43 |
| 52 Week Range | 7.20 - 15.43 |
| Volume | |
| Avg. Volume | 2,793,404 |
| Market Cap | 1.579B |
| Beta (5Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.22 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.15 |
Fair Value
Related Research
GlobeNewswireBioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:30 p.m. ET in New York. Links to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral, small-molecu
- GlobeNewswire
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) congress which is being held in Hamburg, Germany from June 9 – 11, 2023. BioCryst will present two posters at Thematic Poster Session (TPS)
- GlobeNewswire
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile
RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older. “Today’s announcement marks the first approval of ORLADEYO in Latin America, which is an important step forward in addressing the significant unmet
Simply Wall St.BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) institutional shareholders had a great week as one-year returns increased after a 13% gain last week
Key Insights Given the large stake in the stock by institutions, BioCryst Pharmaceuticals' stock price might be...
- GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 34,000 shares, and restricted stock units (RSUs) covering an aggregate of 23,800 shares, of BioCryst common stock. The options and RSUs were granted as of April 28, 2023, as inducements material to each employee entering into employme
Motley FoolBioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX)Q1 2023 Earnings CallMay 03, 2023, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to the BioCryst Q1 2023 earnings conference call.
Motley FoolWhy BioCryst Pharmaceuticals Stock Is Soaring Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a healthy 14% as of 1:40 p.m. ET Wednesday. Although it missed Wall Street's consensus top-line estimate by $2.6 million for the quarter, investors appear to be more concerned about BioCryst's overall financial health and near-term outlook. BioCryst said that in Q1, the number of U.S. patients taking its oral hereditary angioedema (HAE) drug Orladeyo rose by 46% year over year.
- GlobeNewswire
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
—Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million— —Strong ORLADEYO new patient growth in Q1: 46 percent increase in patients on therapy y-o-y, including eight percent growth q-o-q— —Over 1,000 U.S. patients on ORLADEYO therapy— —ORLADEYO net revenue in 2023 expected to be no less than $320 million— RESEARCH TRIANGLE PARK, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31,
ZacksCollegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)
Long-term prophylaxis with ORLADEYO continues to help patients achieve consistently high attack-free days regardless of gender, age and prior HAE therapy after 96 weeks of treatmentRESEARCH TRIANGLE PARK, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S clinical trial, which evaluated oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE), showing sustained reduction in
ZacksWill BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
BioCryst to Report First Quarter 2023 Financial Results on May 3
RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A l
- GlobeNewswire
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP. BioCryst has elected to draw $300 million of the $450 million available to the company on the closing date. The remaining $150 million of committed capital can be drawn at the company’s option until September 2024. Net proceeds to the company at closing will be
- Simply Wall St.
Lacklustre Performance Is Driving BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/S
BioCryst Pharmaceuticals, Inc.'s ( NASDAQ:BCRX ) price-to-sales (or "P/S") ratio of 5.6x might make it look like a...
- GlobeNewswire
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences: The 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th at 8:45 a.m. ET The BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10th at 6:00 p.m. ET The JMP Securities Life Sciences Conference in New York on Tuesday, May 16th at 2:30 p.m. ET The RBC Capital
- GlobeNewswire
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. “I am honored to succeed Bob Ingram. He was a model of effective board leadership for us. Our board is comprised of exceptional people with diverse experience and I am excited to continue working alongside them and the management team to deliver innovative new therapies to pati
- GlobeNewswire
BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success
RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions of Robert A. Ingram, the company’s chairman of the board, who recently passed away. We are very saddened by his loss and our thoughts and prayers go to Bob’s wife Jeanie and his sons Cameron, Michael and Rory. Bob served as a board member since 2015 and chairman since 2017 and played a central role in recruiting highly accomplished board members
- GlobeNewswire
CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada
INTENDED FOR CANADIAN AUDIENCES ONLY RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for ORLADEYO® (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. “We are still in
- GlobeNewswire
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0 attacks per month in 20 of 24 months — RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S and APeX-2 clinical trials which evaluated oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) demonstrating sustained reductions in attack r
Insider MonkeyBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Call Transcript February 21, 2023 Operator: Good morning and welcome to the BioCryst Fourth Quarter 2022 Earnings Conference Call. Please note this event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead. John Bluth: Thanks, Andrea. Good […]
American City Business JournalsBioCryst sees drug sales double but faces R&D setbacks
BioCryst says it's on a path toward a $1 billion drug even as it struggles to advance a pipeline of new products.
Motley FoolWhy Shares of BioCryst Pharmaceuticals Jumped Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were up 12% Wednesday afternoon, a day after the commercial-stage biotech released full-year and fourth-quarter earnings. The stock dropped as much as 17.1% on Tuesday after the earnings report, but Wednesday, it bounced back as much as 14% over the day before. Needham upgraded the stock to "buy" from "hold," adding a $14 price target, and H.C. Wainwright analyst Andrew Fein set a price target of $30 on the stock and reiterated his buy rating.
BenzingaAnalyst Sees Attractive Entry Opportunity After BioCryst's Pipeline Setback
Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a setback on the early-stage BCX10013 study. The company noted recent dose-related observations in an ongoing BCX10013 nonclinical study would delay the clinical program. BioCryst planned to advance BCX10013 into patient studies in mid-2023, including in patients with paroxysmal nocturnal hemoglobinuria (PNH), to evaluate once-daily dosing. In January, the company announced initial data from ongoing pha
- Simply Wall St.
BioCryst Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
BioCryst Pharmaceuticals ( NASDAQ:BCRX ) Full Year 2022 Results Key Financial Results Revenue: US$270.8m (up 72% from...
Motley FoolWhy BioCryst Pharmaceuticals Stock Is Sinking Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are sinking today, down by 17.1% as of 11:09 a.m. ET. The big decline came after the drugmaker announced its fourth-quarter and full-year 2022 results before the market opened. BioCryst reported Q4 revenue of $79.5 million, up from $47.2 million in the prior-year period.